-
Mashup Score: 02023 CCTA - 5 month(s) ago
This is “2023 CCTA” by MedCenterNetwork on Vimeo, the home for high quality videos and the people who love them.
Source: vimeo.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Middle East and Africa Region Earns Bragging Rights with Most Points During 2023 Wellness Challenge - ILCN.org (ILCN/WCLC) - 5 month(s) ago
The challenge, Step It Up for Research, helped WCLC 23 attendees stay active during the meeting while raising money to support the IASLC Foundation, which provides grants for research, education, and other scientific initiatives.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Ceralasertib/Durvalumab Demonstrates Efficacy in RAS-Mutant Advanced NSCLC Post Immune Checkpoint Blockade - 5 month(s) ago
Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Ceralasertib/Durvalumab Demonstrates Efficacy in RAS-Mutant Advanced NSCLC Post Immune Checkpoint Blockade - 5 month(s) ago
Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dendritic Cell Vaccination Fails to Improve OS, Still Bolsters Immune Activation in Mesothelioma - 5 month(s) ago
Joachim G. J. V. Aerts, MD, PhD, discusses how dendritic cell vaccines could bolster historically poor responses to immunotherapy in patients with mesothelioma, reports and provides potential explanations for negative results from the DENIM trial, and details a potential role for this therapy in earlier lines of mesothelioma treatment.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HANSE: effectiveness of NELSON vs. PLCOm2012 lung cancer screening - 5 month(s) ago
Jens Vogel-Claussen, MD, Hannover Medical School, Hannover, Germany, discusses final results from the German HANSE study (NCT04913155), which aimed to assess the effectiveness of two different eligibility criteria models for lung cancer screening: the Netherlands Leuvens Longkanker Screenings Onderzoek (NELSON) and PLCOm2012 models. The PLCOm2012 criteria were found to be reliable and more efficient, suggesting their preference for identifying high-risk individuals in lung cancer screening programs. Longitudinal outcome analysis is planned for further assessment. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Targeting non-G12C KRAS mutations in NSCLC - 6 month(s) ago
Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest developments in targeting non-G12C KRAS mutations in the treatment of non-small cell lung cancer (NSCLC). This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The role of radiotherapy in treating local regional NSCLC - 6 month(s) ago
Shalini Vinod, MBBS, University of New South Wales, Sydney, Australia, outlines the importance of radiotherapy in treating local regional non-small cell lung cancer (NSCLC). The treatment of lung cancer often places an emphasis on systemic therapies and surgeries, causing radiotherapy to become an understated modality. Radiotherapy is crucial in locally advanced lung cancer such as stage III NSCLC. Dr Vinod emphasises that the late presentations and stages of lung cancer result in radiotherapy playing a greater role in treatment than surgery. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Checkpoint Inhibitors Offer Limited Benefit in EGFR-Mutated Lung Cancer After Disease Progression - The ASCO Post - 6 month(s) ago
In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 World Lung Cancer Conference suggest this approach is of limited benefit in this subset. IMpower151, where 52% of patients had EGFR -mutant lung cancer, did not meet its primary endpoint of
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
This webinar will include a sampling of patient advocate research abstracts from presented at the 2023 IASLC World Conference on Lung Cancer (WCLC23) in Singapo …
Source: www.iaslc.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us for an IASLC/STARS webinar including sampling of patient advocate research abstracts presented during #WCLC23 & a live Q&A session moderated by #lungcancer patient/research advocate @JFreemanDaily: https://t.co/J8KHKBDcZ9 #LCSM @jillfeldman4 @BairdAM @ProjectBreath #LCSM https://t.co/kfuBrXpjsT
-
Honoring the 2023 @IASLC CCTA award recipients for patient-centered care at #WCLC23. Congratulations to all for their unwavering commitment. Watch the video: https://t.co/u6ZDjy6GW3 https://t.co/2iosYjMuec